Drug Interactions between Lonsurf and prochlorperazine

MONITOR: Coadministration with inhibitors of the organic cation 2 (OCT2) or multidrug and toxin extrusion 1 (MATE1) transporters may theoretically increase the plasma concentrations of tipiracil, an in vitro substrate of these transporters. Tipiracil is a thymidine phosphorylase inhibitor and is administered in combination with the antineoplastic thymidine-based nucleoside analog, trifluridine, to increase the systemic exposure of trifluridine. Increased levels of tipiracil may therefore further increase the systemic exposure of trifluridine, and the risk of adverse effects such as myelosuppression and gastrointestinal toxicity.

MANAGEMENT: Although the clinical significance is unknown, caution is advised if the combination of tipiracil and trifluridine is used concomitantly with drugs that are inhibitors of OCT2 and/or MATE1. Patients should be monitored for adverse effects including excessive bone marrow suppression and gastrointestinal toxicity. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.